ArticleRadiological physics and technology2026
Retrospective analysis on large-scale in-vivo dosimetric verification of total body irradiation using helical tomotherapy with optically stimulated luminescence dosimeters.
Article in Radiological physics and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To perform a large-scale clinical evaluation of OSLD-based in-vivo dosimetry for helical TomoTherapy-based total body irradiation, focusing on patient thickness, anatomical region, junction stability, and fraction-wise consistency. In-vivo dosimetric data from 250 patients treated with TomoTherapy-based TBI were retrospectively analyzed. RadPro myOSLD nanoDots were placed at multiple anatomical sites,including three junction regions, and measured across all treatment fractions.Percentage dose deviation between measured and expected dose was calculated.Subgroup analyses were performed by anatomical region, junction versus non-junction sites, first versus subsequent fractions, and patient thickness(thin vs obese).Statistical analyses included pass-rate evaluation, Spearman correlation,Mann–Whitney U testing, and Bland–Altman analysis. Mean dose deviations were within ±2% with standard deviations of ~4%, and pass rates within ± 7% and ± 10% were 100%. Dose deviation correlated positively with patient thickness (ρ = 0.34, p < 0.001).Junction regions and fractions showed stable performance. OSLD-based in-vivo dosimetry is a reliable and scalable method for verifying dose delivery in TomoTherapy-based TBI.
Indexed as
Identifiers
41746496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.